Magistral drug preparation offers a model to circumvent many of the technological, regulatory and financial challenges that prevent provision of the right drug at the right time to the right patient.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
05 June 2017
In the version of this article initially published, the line “Editor’s note: This article has been peer-reviewed.” was omitted. The error has been corrected in the HTML and PDF versions of the article.
References
Olfson, M. & Marcus, S.C. Health Aff. (Millwood) 32, 1116–1125 (2013).
Le Tourneau, C. et al. Lancet Oncol. 16, 1324–1334 (2015).
Pirmohamed, M. et al. Br. Med. J. 329, 15–19 (2004).
Jameson, J. & Longo, D.L. N. Engl. J. Med. 372, 2229–2234 (2015).
Faulkner, E. et al. Value Health 15, 1162–1171 (2012).
Carrera, P.M. & Ormond, M. Maturitas 82, 94–99 (2015).
Cohen, J.P. Nat. Biotechnol. 29, 751–756 (2012).
de Bono, J.S. & Ashworth, A. Nature 467, 543–549 (2010).
Damkier, P. Int. J. Clin. Pharm. 37, 669–670 (2015).
Collins, F.S. & Varmus, H. N. Engl. J. Med. 372, 793–795 (2015).
Okie, S. N. Engl. J. Med. 361, 737–740 (2009).
Avorn, J. N. Engl. J. Med. 367, 193–197 (2012).
Frueh, F.W. Value Health 16 Suppl, S27–S31 (2013).
Fleck, L.M. Urol. Oncol. 32, 202–206 (2014).
Kalia, M. Metabolism 62 Suppl 1, S1–14 (2013).
Moors, E.H., Cohen, A.F. & Schellekens, H. Drug Discov. Today 19, 1711–1720 (2014).
European Public Assessment Report Glybera (EMA Website)
Aronson, N. Ann. NY Acad. Sci. 1346, 81–89 (2015).
Abernethy, A. et al. Clin. Cancer Res. 20, 1081–1086 (2014).
Steger, K. et al. J. Biomol. Screen. 20, 545–551 (2015).
Ge, X. et al. J. Am. Chem. Soc. 127, 11228–11229 (2005).
Topol, E.J. N. Engl. J. Med. 351, 1707–1709 (2004).
Minghetti, P., Pantano, D., Gennari, C.G. & Casiraghi, A. Health Policy 117, 328–333 (2014).
Qureshi, N., Wesolowicz, L., Stievater, T. & Lin, A.T. J. Manag. Care Spec. Pharm. 20, 1183–1191 (2014).
McKoy, J.M. et al. Transfusion 48, 1754–1762 (2008).
Kooijman, M., van Meer, P.J., Moors, E.H. & Schellekens, H. Expert Opin. Drug Saf. 11, 797–801 (2012).
van Meer, P.J. et al. MAbs 5, 810–816 (2013).
Schneider, C.K. & Kalinke, U. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 50, 1213–1220 (2007).
Patten, P.A. & Schellekens, H. Dev. Biol. 112, 81–97 (2003).
Bach, P.B., Conti, R.M., Muller, R.J., Schnorr, G.C. & Saltz, L.B. Br. Med. J. 352, i788 (2016).
Ciriminna, R. et al. Nanoscale 6, 6293–6300 (2014).
Gising, J., Odell, L.R. & Larhed, M. Org. Biomol. Chem. 10, 2713–2729 (2012).
Szymkuć, S. et al. Angew. Chem. Int. Edn Engl. 55, 5904–5937 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Schellekens, H., Aldosari, M., Talsma, H. et al. Making individualized drugs a reality. Nat Biotechnol 35, 507–513 (2017). https://doi.org/10.1038/nbt.3888
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3888